



Neu-QAP

(an EXTERNAL QUALITY ASSURANCE PROGRAMME)



NABL
ISO/IEC 17043:2010
accredited
PC-1047

PARTICIPANT FINAL ASSESSMENT REPORT

PT SCHEME: SEROLOGY

Cycle No	C2
Ref.No.	NEUQAP411
Sample ID	NEUQAP SERO SERUM/2020/10/C2/S4

Report Date : 24/11/2020

Sample : October 2020

All Methods

Parameters	Lab Report	No of Participants	Consensus Report	%	Remarks
Brucella	Not Recvd.	27	Non Reactive - 27		
Brucella Antigen	Not Recvd.	3	Non Reactive - 2 Reactive - 1		
Brucella IgG	Not Recvd.	18	Non Reactive - 17 Reactive - 1		
Brucella IgM	Not Recvd.	18	Non Reactive - 18		
Chikungunya	Not Recvd.	46	Negative - 45 Positive - 1		
CMV IgG	Not Recvd.	44	Reactive - 44		
CMV IgM	Not Recvd.	46	Non Reactive - 46		
HBsAg	Reactive	132	Non Reactive - 1 Reactive - 131	99	Within Consensus
HCV	Reactive	130	Equivocal - 2 Non Reactive - 36 Reactive - 92	71	Within Consensus
HIV-1	Reactive	131	Equivocal - 2 Non Reactive - 8 Reactive - 121	92	Within Consensus
Rubella IgG	Not Recvd.	45	Reactive - 45		
Rubella IgM	Not Recvd.	44	Non Reactive - 44		
Toxoplasma IgG	Not Recvd.	43	Non Reactive - 1 Reactive - 42		
Toxoplasma IgM	Not Recvd.	44	Non Reactive - 44		

Authorised Signatory

Dr. Sujay Prasad

Technical Manager and Program coordinator

Page 1 of 3

This report is for use only by the intended participant.



An external quality assurance program from
NEUBERG ANAND ACADEMY OF LABORATORY MEDICINE PVT.LTD.

Anand Tower, 54, Bowring Hospital Road,
Shivajinagar, Bangalore - 560001
+91-9902277355 · qap@naalm.com · www.naalm.com
CIN: U85300KA2018PTC115147



Neu-QAP

(an EXTERNAL QUALITY ASSURANCE PROGRAMME)

PARTICIPANT FINAL ASSESSMENT REPORT

PT SCHEME: SEROLOGY



Cycle No	C2
Ref.No.	NEUQAP411
Sample ID	NEUQAP SERO SERUM/2020/10/C2/S4

Report Date : 24/11/2020

Sample : October 2020

All Methods

Parameters	Lab Report	No of Participants	Consensus Report	%	Remarks
VDRL	Non Reactive	126	Non Reactive - 98 Reactive - 28	78	Within Consensus
Weil Felix OX19	Not Recvd.	39	Negative - 38 Positive - 1		
Weil Felix OX2	Not Recvd.	41	Negative - 38 Positive - 3		
Weil Felix OXK	Not Recvd.	38	Negative - 36 Positive - 2		
Widal	Negative	127	Negative - 126 Positive - 1	99	Within Consensus

Authorised Signatory

Dr. Sujay Prasad
Technical Manager and Program coordinator

Page 2 of 3

This report is for use only by the intended participant.



An external quality assurance program from
NEUBERG ANAND ACADEMY OF LABORATORY MEDICINE PVT.LTD.

Anand Tower, 54, Bowring Hospital Road,
Shivajinagar, Bangalore - 560001
+91-9902277355 - qap@naalm.com - www.naalm.com
CIN: U85300KA2018PTC115147

Neu-QAP

(an EXTERNAL QUALITY ASSURANCE PROGRAMME)

PARTICIPANT FINAL ASSESSMENT REPORT

PT SCHEME: SEROLOGY



ISO/IEC 17043:2010
accredited
PC-1047

Cycle No	C2
Ref.No.	NEUQAP411
Sample ID	NEUQAP SERO SERUM/2020/10/C2/S4

Report Date : 24/11/2020

Sample : October 2020

Peer group

Parameters	Lab Report	No of Participants	Consensus Report	%	Remarks
HBsAg (Chemiluminescence)	Reactive	47	Reactive - 47	100	Within Consensus
HCV (Chemiluminescence)	Reactive	46	Non Reactive - 1 Reactive - 45	98	Within Consensus
HIV-1 (CLIA)	Reactive	7	Reactive - 7	100	Within Consensus
VDRL (Flocculation)	Non Reactive	110	Non Reactive - 94 Reactive - 16	85	Within Consensus
Widal (Tube Agglutination)	Negative	69	Negative - 69	100	Within Consensus

Note: Sample generation, homogeneity and stability testing are subcontracted to accredited laboratories

**End of report **

Authorised Signatory

Dr. Sujay Prasad

Technical Manager and Program coordinator

Page 3 of 3

This report is for use only by the intended participant.



An external quality assurance program from
NEUBERG ANAND ACADEMY OF LABORATORY MEDICINE PVT.LTD.

Anand Tower, 54, Bowring Hospital Road,
Shivajinagar, Bangalore - 560001
+91-9902277355 · qap@naalm.com · www.naalm.com
CIN: U85300KA2018PTC115147